Prestige Consumer Healthcare stock cuts fiscal 2027 outlook
Published on 11/10/2026 at 01:12 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSResults Reset Fiscal 2027 Expectations
- Prestige reported strong headline revenue growth as the Breathe Right and LaCorium acquisitions added sales.
- Organic revenue declined in the quarter, with Clear Eyes production issues weighing on the outlook.
- Management expects lower full-year revenue, adjusted earnings and free cash flow than previously forecast.
Prestige Consumer Healthcare reported second-quarter and first-half fiscal 2027 results on Thursday, November 5, for the period ended September 30. In its earnings release, the company said revenue rose 22.7 percent to 336.3 million US dollars, supported by the Breathe Right portfolio and LaCorium acquisitions.
Acquisitions Lift Reported Revenue
Reported revenue growth masked a weaker underlying trend. Excluding foreign exchange and 65.1 million US dollars of acquisition revenue, quarterly revenue declined 1.6 percent. Management attributed the organic performance to order timing in the first quarter and lower Clear Eyes sales.
Reported diluted earnings per share fell to 0.53 US dollars from 0.86 US dollars a year earlier. Adjusted diluted earnings per share increased to 1.13 US dollars from 1.07 US dollars, with the reconciliation including acquisition costs, Pillar5 facility remediation and idle-capacity expenses, debt extinguishment costs and tax adjustments.
Clear Eyes Drives Guidance Cut
Prestige lowered its fiscal 2027 revenue outlook to 1.28 billion to 1.29 billion US dollars from 1.29 billion to 1.315 billion US dollars. The adjusted diluted earnings-per-share range was reduced to 4.48 to 4.55 US dollars from 4.55 to 4.65 US dollars, while adjusted free cash flow is now expected to reach at least 265 million US dollars, compared with at least 270 million US dollars previously.
Chief Executive Ron Lombardi said production variability at the acquired Pillar5 facility was expected to reduce Clear Eyes product availability and revenue in the second half. The company said the remainder of its portfolio and the recent acquisitions remained aligned with its previous expectations.
Position In Consumer Healthcare
Prestige Consumer Healthcare markets, sells, manufactures and distributes branded over-the-counter products in the United States, Canada, Australia and selected other international markets, according to its investor-relations site. Its portfolio includes Dramamine, Monistat, Summer's Eve, Clear Eyes, TheraTears and Compound W.
Morningstar describes Prestige as one of the largest pure-play over-the-counter healthcare providers, focused on niche categories rather than the blockbuster brands of larger consumer-goods groups. It lists Procter & Gamble, Haleon and Kenvue as competitors, giving Prestige a more specialized position within the consumer-health market.
Prestige Consumer Healthcare at a Glance
- Company: Prestige Consumer Healthcare Inc.
- Ticker: PBH
- Reporting period: Second quarter and first half fiscal 2027 ended September 30, 2026
- Quarterly revenue: 336.3 million US dollars, up 22.7 percent year over year
- Adjusted diluted EPS: 1.13 US dollars
- Fiscal 2027 revenue outlook: 1.28 billion to 1.29 billion US dollars
- Fiscal 2027 adjusted diluted EPS outlook: 4.48 to 4.55 US dollars
US equity investors also monitor the broader S&P 500 market environment as consumer-health companies navigate demand, supply and retail conditions.
